Research Analysts Offer Predictions for ATNM FY2025 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright raised their FY2025 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Monday, November 17th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.09) per share for the year, up from their previous forecast of ($1.26). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.91) EPS.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $1.43 on Wednesday. The firm has a market cap of $44.61 million, a PE ratio of -1.03 and a beta of -0.25. The firm’s 50 day moving average price is $1.51 and its 200-day moving average price is $1.58. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $2.41.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Large investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares during the period. AM Investment Strategies LLC boosted its stake in Actinium Pharmaceuticals by 114.1% during the first quarter. AM Investment Strategies LLC now owns 30,872 shares of the company’s stock worth $50,000 after buying an additional 16,450 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Actinium Pharmaceuticals by 35.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 97,604 shares of the company’s stock valued at $157,000 after acquiring an additional 25,511 shares during the last quarter. Gagnon Securities LLC purchased a new stake in shares of Actinium Pharmaceuticals in the 1st quarter valued at approximately $365,000. Finally, Invesco Ltd. raised its stake in shares of Actinium Pharmaceuticals by 1,135.9% in the 1st quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock valued at $247,000 after acquiring an additional 141,130 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).